Advancing mediastinal sampling in non-metastatic lymphadenopathy.
1/5 보강
Despite advances in PET/CT, tissue confirmation remains essential for mediastinal lymphadenopathy.
APA
Engeli R, Steinack C, et al. (2026). Advancing mediastinal sampling in non-metastatic lymphadenopathy.. Med (New York, N.Y.), 7(2), 101025. https://doi.org/10.1016/j.medj.2026.101025
MLA
Engeli R, et al.. "Advancing mediastinal sampling in non-metastatic lymphadenopathy.." Med (New York, N.Y.), vol. 7, no. 2, 2026, pp. 101025.
PMID
41690294 ↗
Abstract 한글 요약
Despite advances in PET/CT, tissue confirmation remains essential for mediastinal lymphadenopathy. EBUS-TBNA is minimally invasive but limited by cytology, particularly in benign disease and lymphoma. Emerging EBUS-guided techniques, notably transbronchial mediastinal cryobiopsy, improve diagnostic yield where tissue architecture is required. The multicenter randomized study strengthens evidence for its added value, while underscoring the need for selective application and standardized, indication-specific trials.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.